Studies utilizing brief analytical treatment interruption (ATI) of cART in HIV-1 infected subject have consistently shown that viral rebound occurs rapidly upon treatment interruption. The viral dynamics and relevant host immune pressures at this juncture, however, remain unclear. To test the hypothesis that the autologous antibody response is a significant driver of virus selection during ATI, we identify the viral populations arising from latency and measure the potency and kinetics of the autologous antibody response.
Plasma samples from 11 chronically infected, cART-suppressed subjects undergoing ATI were studied by single genome sequencing (SGS) and maximum likelihood analysis of gp160 env. Consensus envs from each lineage were cloned and tested for neutralization sensitivity in TZM-bl assays.
We generated 231 SGS-derived envs (range: 16-29/subject timepoint). Multiple low-diversity lineages (2 to >10/subject) comprised the rebound quasispecies at first detectable viremia. Envs representing initial rebound lineages displayed a range of neutralization sensitivities to autologous plasmas (IC50 <1:50 to >1:5,000). In three subjects studied over 12 weeks of ATI, neutralization resistant viruses persisted while more sensitive lineages substantially decreased in frequency. For example, subject S05 rebounded with four genetically distinct lineages (total env diversity of 1.48%; within-lineage diversity of <0.17%); each lineage was moderately sensitive to week 4 plasma (IC50 range: 1:240-1:420). Over time, titers to the largest lineage (8/20 sequences at week 4) rose to >1:3000 and this lineage was not sampled subsequently (0/18 sequences, week 10). Minor lineages, in contrast, became more resistant to longitudinal plasmas (IC50 ~1:100 to week 10 plasma) and expanded to comprise the majority of the viral quasispecies (15/18 sequences, week 10).
This study demonstrates that HIV-infected individuals undergoing ATI have multiple genetically distinct rebounding viral lineages exhibiting a range of sensitivities to autologous antibodies. Results suggest that the autologous neutralizing antibody response during ATI exerts potent selective pressure and is a significant factor determining viral quasispecies composition. These findings contribute to our understanding of relevant immune pressures during ATI and suggest that autologous antibodies may contribute to virus suppression achieved with novel immunotherapies currently being tested in the context of ATI.